About Lynx Therapeutics
Lynx Therapeutics is a Healthcare company based in Hayward (United States) founded in 1992, and was acquired by Solexa in September 2004. Molecular sequence diagnostics are developed for life science sectors. Lynx Therapeutics has raised $56.7 million across 6 funding rounds from investors including SVB, Solexa and Chiron Investment Management. Lynx Therapeutics offers products and services including Assay Kits, Antibodies, and Enzymes. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Kits and Reagents. Its legal entity is Solexa, Inc. Its competitors include Bio Rad, Quanterix and GenScript; 2 of its 3 listed competitors have raised funding.
Company details
The company was founded in 1992 and is headquartered in Hayward, United States. Operations focus on the development and application of genomics analysis solutions within the life sciences industry. Proprietary cloning and sequencing technologies, including Massively Parallel Signature Sequencing (MPSS) and Mega clone, form the basis of these solutions. Collaborations have been established with E.I. DuPont de Nemours and Company, Bayer CropScience, and Takara Bio to advance molecular sequence diagnostics.
- Headquarters Hayward, United States
- Stage Acquired
- SectorsHealthcare
- Website lynxgen.com
- Social LinkedIn
- Acquired by Solexa (Sep 2004)
- Legal Name Solexa, Inc
Products & Services of Lynx Therapeutics
Lynx Therapeutics offers a comprehensive portfolio of products and services, including Assay Kits, Antibodies, and Enzymes.
Kits for testing glycans and proteins in biotechnology research applications.
Proteins used for detection in glycobiology and molecular analysis studies.
Substances that facilitate biomolecular reactions in research settings.
Funding Insights of Lynx Therapeutics
Lynx Therapeutics has successfully raised a total of $56.7M across 6 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $3 million completed in December 2004. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $56.7M
- Total Rounds 6
- Last Round Debt – Conventional — $3M
- First Round $6M
(Apr 1995)
- Investors Count 4
All 6 funding rounds of Lynx Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2004 | $3M | Debt – Conventional | – | – | |
| Jan 2004 | $4M | Series C | – | – | – |
| Apr 2002 | $22.6M | Series C | – | – | – |
| May 2001 | $11.1M | Series B | – | – | |
| Jul 1999 | $13M | Series B | – | Applied Biosystems | |
| Apr 1995 | $6M | Series A | – | – | – |
5 investors in total: 5 institutional.
Investors in Lynx Therapeutics
Lynx Therapeutics has secured backing from 5 investors, including institutional investors. Prominent investors backing the company include SVB, Solexa and Chiron Investment Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Banking services are provided to innovative companies, investors, and individuals. | 1983 | svb.com | Santa Clara, United States | |
Investment management firm providing financial strategies and portfolio services globally. | 1995 | hbk.com | Dallas, United States | |
Instruments, assays, and reagents for life science research are supplied. | 1997 | appliedbiosystems.com | Newport Beach, United States | |
Investment research services are provided to clients. | 2007 | chironim.com | Leawood, United States | |
Develops Genome sequencing technology | 1992 | solexa.com | Hayward, United States |
Investor details for Lynx Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Lynx Therapeutics
4 dated milestones of Lynx Therapeutics across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Lynx Therapeutics is founded.
- Funding First funding round of $6.0M.
- Exit Acquired by Solexa.
- Funding Latest funding round, Debt – Conventional, of $3.0M.
Competitors of Lynx Therapeutics
Lynx Therapeutics has 3 listed competitors in our database, 2 of them funded. They include Bio Rad, Quanterix and GenScript.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bio-rad.com | 1952 | Hercules, United States | 10 | Portfolio of products and services for life science research and clinical diagnostic markets | ||
| quanterix.com | 2007 | Cambridge, United States | $99.5M | 141 | Assay kits for ultra-sensitive biomarker detection are developed. | |
| genscript.com | 2002 | Piscataway, United States | $15M | 5,260 | Reagents and instruments are provided for life sciences research. |
Detailed competitors of Lynx Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Lynx Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Lynx Therapeutics
Lynx Therapeutics was founded in 1992 and raised its 1st funding round 3 years after it was founded.
Lynx Therapeutics is headquartered in Hayward, United States. It is registered at Hayward, California, United States.
Lynx Therapeutics is a funded company, having raised a total of $56.7M across 6 funding rounds to date. The company's 1st funding round was a Series A of $6M, raised on Apr 1995.
The company was founded in 1992 and is headquartered in Hayward, United States. Operations focus on the development and application of genomics analysis solutions within the life sciences industry. Proprietary cloning and sequencing technologies, including Massively Parallel Signature Sequencing (MPSS) and Mega clone, form the basis of these solutions. Collaborations have been established with E.I. DuPont de Nemours and Company, Bayer CropScience, and Takara Bio to advance molecular sequence diagnostics.
Lynx Therapeutics offers Assay Kits, Antibodies, and Enzymes.
Lynx Therapeutics has 5 investors. Key investors include SVB, Solexa, Chiron Investment Management, Applied Biosystems, and Hbk Capital Management.
Lynx Therapeutics operates through Solexa, Inc.
Yes. Lynx Therapeutics was acquired by Solexa in September 2004.